1
|
Abdo AA, Ackermann M, Ajello M, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bouvier A, Brandt TJ, Bregeon J, Brez A, Brigida M, Bruel P, Buehler R, Burnett TH, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Carrigan S, Casandjian JM, Cecchi C, Celik O, Charles E, Chaty S, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Corbel S, Corbet R, DeCesar ME, den Hartog PR, Dermer CD, de Palma F, Digel SW, Donato D, do Couto e Silva E, Drell PS, Dubois R, Dubus G, Dumora D, Favuzzi C, Fegan SJ, Ferrara EC, Fortin P, Frailis M, Fuhrmann L, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guiriec S, Hadasch D, Harding AK, Hayashida M, Hays E, Healey SE, Hill AB, Horan D, Hughes RE, Itoh R, Jean P, Jóhannesson G, Johnson AS, Johnson RP, Johnson TJ, Johnson WN, Kamae T, Katagiri H, Kataoka J, Kerr M, Knödlseder J, Koerding E, Kuss M, Lande J, Latronico L, Lee SH, Lemoine-Goumard M, Garde ML, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Makeev A, Mazziotta MN, McConville W, McEnery JE, Mehault J, Michelson PF, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Naumann-Godo M, Nestoras I, Nolan PL, Norris JP, Nuss E, Ohno M, Ohsugi T, Okumura A, Omodei N, Orlando E, Ormes JF, Ozaki M, Paneque D, Panetta JH, Parent D, Pelassa V, Pepe M, Pesce-Rollins M, Piron F, Porter TA, Rainò S, Rando R, Ray PS, Razzano M, Razzaque S, Rea N, Reimer A, Reimer O, Reposeur T, Ripken J, Ritz S, Romani RW, Roth M, Sadrozinski HFW, Sander A, Parkinson PMS, Scargle JD, Schinzel FK, Sgrò C, Shaw MS, Siskind EJ, Smith DA, Smith PD, Sokolovsky KV, Spandre G, Spinelli P, Stawarz Ł, Strickman MS, Suson DJ, Takahashi H, Takahashi T, Tanaka T, Tanaka Y, Thayer JB, Thayer JG, Thompson DJ, Tibaldo L, Torres DF, Tosti G, Tramacere A, Uchiyama Y, Usher TL, Vandenbroucke J, Vasileiou V, Vilchez N, Vitale V, Waite AP, Wallace E, Wang P, Winer BL, Wolff MT, Wood KS, Yang Z, Ylinen T, Ziegler M, Maehara H, Nishiyama K, Kabashima F, Bach U, Bower GC, Falcone A, Forster JR, Henden A, Kawabata KS, Koubsky P, Mukai K, Nelson T, Oates SR, Sakimoto K, Sasada M, Shenavrin VI, Shore SN, Skinner GK, Sokoloski J, Stroh M, Tatarnikov AM, Uemura M, Wahlgren GM, Yamanaka M. Gamma-ray emission concurrent with the nova in the symbiotic binary V407 Cygni. Science 2010; 329:817-21. [PMID: 20705855 DOI: 10.1126/science.1192537] [Citation(s) in RCA: 146] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Novae are thermonuclear explosions on a white dwarf surface fueled by mass accreted from a companion star. Current physical models posit that shocked expanding gas from the nova shell can produce x-ray emission, but emission at higher energies has not been widely expected. Here, we report the Fermi Large Area Telescope detection of variable gamma-ray emission (0.1 to 10 billion electron volts) from the recently detected optical nova of the symbiotic star V407 Cygni. We propose that the material of the nova shell interacts with the dense ambient medium of the red giant primary and that particles can be accelerated effectively to produce pi(0) decay gamma-rays from proton-proton interactions. Emission involving inverse Compton scattering of the red giant radiation is also considered and is not ruled out.
Collapse
Affiliation(s)
-
- Space Science Division, Naval Research Laboratory, Washington, DC 20375, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Philbin DM, Coggins CH, Wilson N, Sokoloski J. Antidiuretic hormone levels during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1977; 73:145-8. [PMID: 831006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The effect of CPB on plasma ADH levels, urine flow, and urine osmolality was studied in nine patients. All patients received morphine, 1 mg. per kilogram, and 50 per cent nitrous oxide-50 per cent oxygen for anesthesia. CPB utilized a Travenol disposable bubble oxygenator and the prime consisted of 3 L. of Ringer's lactate. Measurements were made prior to induction of anesthesia , at 30 minutes following surgical incision, and at 15, 30, and 45 minutes during CPB. There were no statistically significant changes in mean arterial BP, cardiac index, serum sodium, or serum osmolality in any period. Urine flow increased from 0.99 +/- 0.3 ml. per minute to a high of 6.13 +/- 2.0 ml. per minute at 30 minute at 30 minutes on CPB (P less than 0.02). Urine osmolality declined from a control value of 691 +/- 142 mOsm. per kilogram to a low of 425 +/- 48 mOsm. per kilogram at 45 minutes on CPB (p less than 0.05). ADH levels rose from a control value of 4.3 +/- 1.5 to 13.0 +/- 3.3 pg. per milliliter with surgical stimulatiion (p less than 0.05). During CPB the ADH levels rose to a peak of 23.7 +/- 3.6 pg. per milliliter at 30 minutes (p less than 0.01) and were declining at 45 minutes. These data suggest that the stress of CPB results in an outpouring of ADH (or vasopressin) to function as a pressor to produce an increase in peripheral resistance. The ADH concentrations far exceed those required for normal physiologic control of water excretion and the urineflow will thus vary more with the hemodynamic changes than with the ADH levels.
Collapse
|